

You or someone you love has been diagnosed with an aggressive form of cancer.

Conventional medicine - the “standard of care” - offers little or no hope.

The Jaime Leandro Foundation does.



Traditional vaccines revolutionized the treatment of disease. In recent years, personalized vaccines have shown promise in combating cancer. At the same time, technological advances have become more accessible, and the FDA introduced “expanded access” which gives an individual the right to try a medical treatment outside of clinical trials when no comparable alternative options are available.

The Jaime Leandro Foundation (JLF) is a private nonprofit organization established to deliver breakthrough cancer treatments based on the latest innovations in research and personalized medicine and leveraging the Expanded Access rule — also known as “Compassionate Use.” We bring the critical components together, partnering with expert academic and commercial institutions to develop and deliver therapeutic vaccines personalized for each patient.

In essence, JLF is the hub, and our partners conduct advanced genetic sequencing, identify and approve the best patient-specific neoantigen targets, and manufacture, assemble, vial, and ship the personalized vaccine, which is administered by the treating physician. Then, JLF partners monitor and report results for the advancement of knowledge overall.

LEADERSHIP TEAM

William Hoos
President
Jaime Leandro Foundation

Marty Tenenbaum
Chairman
xCures
Cancer Commons

William Gillanders, MD
Professor of Surgery
Vice Chair, Research
Washington U School of
Medicine in St. Louis

Malachi Griffith, PhD
Professor
Washington U School of
Medicine in St. Louis

Andrew Jacobs
Board Member
ennov1

Andrew Popp
CTO
ennov1

Jason Chang
CEO
CSBio

Jaime Leandro Foundation for Therapeutic Cancer Vaccines

Personalized Neoantigen Vaccines through Expanded Access

info@jaimeleandrofoundation.org | jaimeleandrofoundation.org



COLLABORATORS

JLF partners are at the forefront of medicine and science. Each is an industry leader providing cutting-edge expertise and technology at every step. JLF consults with the patient and helps them navigate the entire process.

Ennov1



xCures

ennov1.com

csbio.com

xcures.com

PROCESS

The JLF process involves industry leaders providing cutting-edge technology at every step. Developing a personalized therapeutic vaccine takes about three months.

PHASE 1: WHOLE EXOME SEQUENCING

TIMING: 4 WEEKS

COST: VARIES BY PROVIDER, JLF CAN HELP WITH CONSULTATION

1




A partner conducts intense DNA sequencing of tumor cell to identify patient-specific targets ("neoantigens")

PHASE 2: VACCINE DESIGN

TIMING: 6 WEEKS


COST: \$20,000

2




ennov1 uses sequencing data and employs algorithms to determine best targets

2a



A genomic analyst reviews findings and selects targets

3



After FDA approval, CSBio manufactures personalized vaccines

3a



A manufacturing lab vials vaccine and ships to treating physician

PHASE 4: VACCINE ADMINISTRATION

TIMING: UP TO 6 MONTHS


COST: \$12,000 PLUS PHYSICIAN ADMINISTRATION FEES

4



Treating physician administers the vaccine

4a




Immune cells learn to recognize the neoantigens in the cancer cells

4b



ELISpot monitoring of immune response is performed

4c



xCures collects data and provides safety reporting

Jaime Leandro Foundation for Therapeutic Cancer Vaccines

Personalized Neoantigen Vaccines through Expanded Access

info@jaimeleandrofoundation.org | jaimeleandrofoundation.org



Click to learn more about Jaime.